Your browser is no longer supported. Please, upgrade your browser.
STTK Shattuck Labs, Inc. monthly Stock Chart
STTK [NASD]
Shattuck Labs, Inc.
Index- P/E- EPS (ttm)- Insider Own0.90% Shs Outstand38.64M Perf Week10.03%
Market Cap1.35B Forward P/E- EPS next Y-1.57 Insider Trans- Shs Float29.24M Perf Month60.85%
Income- PEG- EPS next Q-0.39 Inst Own27.83% Short Float2.24% Perf Quarter-
Sales11.41M P/S118.50 EPS this Y-224.60% Inst Trans- Short Ratio1.99 Perf Half Y-
Book/sh- P/B- EPS next Y16.90% ROA- Target Price35.00 Perf Year-
Cash/sh3.49 P/C10.03 EPS next 5Y- ROE- 52W Range17.51 - 34.43 Perf YTD80.88%
Dividend- P/FCF- EPS past 5Y- ROI72.40% 52W High1.66% Beta-
Dividend %- Quick Ratio8.60 Sales past 5Y- Gross Margin- 52W Low99.89% ATR2.74
Employees57 Current Ratio8.60 Sales Q/Q36.50% Oper. Margin- RSI (14)- Volatility11.55% 11.20%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.36 Prev Close32.58
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume329.21K Price35.00
Recom1.70 SMA2027.14% SMA5040.06% SMA20040.06% Volume121,667 Change7.43%
Nov-03-20Initiated Needham Buy $34
Nov-03-20Initiated Cowen Outperform
Nov-03-20Initiated Citigroup Buy $36
Nov-13-20 06:00AM  
Nov-11-20 09:27AM  
Nov-06-20 08:00AM  
Nov-05-20 08:00AM  
Oct-29-20 08:30AM  
Oct-23-20 05:54PM  
Oct-21-20 06:19PM  
Oct-09-20 03:49PM  
01:28PM  
11:20AM  
Oct-08-20 07:55PM  
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian cancer. It also holds a collaboration agreement with Takeda Pharmaceuticals to develop SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was founded in 2016 and is headquartered in Austin, Texas.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Neill Andrew RSee RemarksNov 05Option Exercise0.012,2112290,677Nov 09 04:30 PM
Thomson Erin AtorGeneral CounselNov 05Option Exercise0.012,95230107,259Nov 09 04:30 PM
Redmile Group, LLCDirectorOct 14Buy17.343,441,17659,669,3435,619,914Oct 15 05:21 PM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 FINVIZ.com. All Rights Reserved.